Stefano Indraccolo Giovanni Randon Elisabetta Zulato Margherita Nardin Camillo Aliberti Fabio Pomerri Alessandra Casarin Maria Ornella Nicoletto
10.1080/15384047.2014.1002366
Cancer Biol Ther
2015;16(2):210-4.
ampk, amp-activated protein kinase ct, computed tomography ec, endometrial cancer lkb1 lkb1, liver kinase b1 mct4 mct4, monocarboxylate transporter 4 os, overall survival pfs, progression free survival tace, trans-catheter arterial chemoembolization vegf vegf-a, vascular endothelial growth factor a antiangiogenic therapy bevacizumab endometrial cancer glycolysis metformin
CC BY-NC
https://pubmed.ncbi.nlm.nih.gov/25607951/
Antineoplastic Agents / therapeutic use Endometrial Neoplasms / drug therapy Metformin / therapeutic use
Antineoplastic Agents / therapeutic use Endometrial Neoplasms / drug therapy Metformin / therapeutic use Case Reports Research Support, Non-U.S. Gov't Angiogenesis Inhibitors / administration & dosage Angiogenesis Inhibitors / therapeutic use Antineoplastic Agents / administration & dosage Antineoplastic Combined Chemotherapy Protocols / therapeutic use Bevacizumab / administration & dosage Bevacizumab / therapeutic use Drug Synergism Endometrial Neoplasms / diagnosis Female Humans Liver Neoplasms / diagnosis Liver Neoplasms / drug therapy Liver Neoplasms / secondary Lung Neoplasms / drug therapy Lung Neoplasms / secondary Metformin / administration & dosage Middle Aged Neoplasm Staging Positron-Emission Tomography Tomography, X-Ray Computed Angiogenesis Inhibitors Antineoplastic Agents Bevacizumab Metformin
PMC4623111
25607951
Metformin: a modulator of bevacizumab activity in cancer? A case report
2015